The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known by brand names Ozempic and Wegovy, has the ability to counter metabolic dysfunction-associated steatohepatitis, or MASH, liver disease and some of its risk factors.

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can significantly improve—and in some cases even reverse—advanced liver disease. The findings come from the ESSENCE Phase III clinical trial,